AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
14 Junho 2023 - 9:45AM
AIM ImmunoTech Inc. (NYSE American:
AIM) (“AIM” or the “Company”), an immuno-pharma
company focused on the research and development of therapeutics to
treat multiple types of cancers, immune disorders, and viral
diseases, including COVID-19, the disease caused by the SARS-CoV-2
virus, today announced that Thomas K Equels, M.S., J.D., Executive
Vice Chairman, Chief Executive Officer & President of AIM
ImmunoTech, will present at the Healthcare Virtual Conference Part
II, presented by Maxim Group LLC and hosted by M-Vest on Wednesday,
June 21, 2023 at 12:00 PM ET.
The exponential growth in knowledge and
expertise in science and medicine continues to drive opportunities
in the healthcare space. These include multiple therapeutic
categories and emerging technologies, which presenting companies at
this year’s Maxim Healthcare Conference are focused on, and for
many, that includes key data-driven events in 2023. Maxim Senior
Analysts will host a wide range of biotechnology and medical device
companies in a series of presentations and interactive discussions
with CEOs and key management. Maxim will also be hosting several
topical industry panels that promise to be timely and engaging.
This conference will be live on M-Vest. To
attend, just sign up to become an M-Vest member.
Click Here to Reserve Your Seat. About
AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders and viral diseases,
including COVID-19. The Company’s lead product is a first-in-class
investigational drug called Ampligen® (rintatolimod), a dsRNA and
highly selective TLR3 agonist immuno-modulator with broad spectrum
activity in clinical trials for globally important cancers, viral
diseases and disorders of the immune system.
For more information, please
visit aimimmuno.com and connect with the Company
on Twitter, LinkedIn, and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
AIM ImmunoTech (AMEX:AIM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024